Annals of Military and Health Sciences Research

Published by: Kowsar

Evaluation of the PADUA Prediction Score in Vein Thromboembolism Prophylaxis in Patients Admitted to Imam Reza Hospital in 2017

Adel Joharimoghadam 1 , Hedayat Allah Valimanesh 2 , * , Amirabbas Sheykhalo 3 , ** , Seyed Hossein Musavi 1 and Ebad Shiri 4
Authors Information
1 Cardiovascular Department, AJA University of Medical Sciences, Tehran, Iran
2 Internal Medicine Department, AJA University of Medical Sciences, Tehran, Iran
3 General Practitioner Department, AJA University of Medical Sciences, Tehran, Iran
4 Social Medicine Department, AJA University of Medical Sciences, Tehran, Iran
Corresponding Authors:
Article information
  • Annals of Military and Health Sciences Research: September 2018, 16 (3); e83034
  • Published Online: November 26, 2018
  • Article Type: Research Article
  • Received: August 7, 2018
  • Revised: November 18, 2018
  • Accepted: November 18, 2018
  • DOI: 10.5812/amh.83034

To Cite: Joharimoghadam A, Valimanesh H A, Sheykhalo A, Musavi S H, Shiri E. Evaluation of the PADUA Prediction Score in Vein Thromboembolism Prophylaxis in Patients Admitted to Imam Reza Hospital in 2017, Ann Mil Health Sci Res. 2018 ; 16(3):e83034. doi: 10.5812/amh.83034.

Abstract
Copyright © 2018, Annals of Military and Health Sciences Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
References
  • 1. koucheck M, Alavi Moghadam M, Heidari F, Ahmadinejad M, Miri MM. [Cumulative incidence of venous thromboembolism in a teaching general ICU in Tehran]. Pajoohandeh J. 2011;16(3):134-8. Persian.
  • 2. Molahosseini Kahnoji R, Nikoobakht M. [The frequency assessment of deep vein thrombosis and its associated risk factors in patients undergoing neurosurgical procedures]. Razi J Med Sci. 2010;17(77):74-80. Persian.
  • 3. Farzamnia H, Rabiei K, Sadeghi M, Roghani F. The predictive factors of recurrent deep vein thrombosis. ARYA Atheroscler. 2011;7(3):123-8. [PubMed: 22577459]. [PubMed Central: PMC3347857].
  • 4. Depietri L, Marietta M, Scarlini S, Marcacci M, Corradini E, Pietrangelo A, et al. Clinical impact of application of risk assessment models (Padua prediction score and improve bleeding score) on venous thromboembolism, major hemorrhage and health expenditure associated with pharmacologic VTE prophylaxis: A “real life” prospective and retrospective observational study on patients hospitalized in a single internal medicine unit (the STIME study). Intern Emerg Med. 2018;13(4):527-34. doi: 10.1007/s11739-018-1808-z.
  • 5. Spyropoulos AC, Anderson FA Jr, FitzGerald G, Decousus H, Pini M, Chong BH, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706-14. doi: 10.1378/chest.10-1944. [PubMed: 21436241].
  • 6. Bikdeli B, Sharif-Kashani B, Shahabi P, Raeissi S, Shahrivari M, Shoraka AR, et al. Comparison of three risk assessment methods for venous thromboembolism prophylaxis. Blood Coagul Fibrin. 2013;24(2):157-63. doi: 10.1097/MBC.0b013e32835aef7e.
  • 7. Franca A, Reis A, Paulino A, Lohman C, Cartucho D, Campello G, et al. Venous thromboembolism risk factors and practices of prophylaxis: ENDORSE study results in Portugal. Acta Med Port. 2011;24(6):951-60. [PubMed: 22713190].
  • 8. Musial J, Sydor WJ; Endorse Investigators-Poland. Venous thromboembolism risk and prophylaxis in the acute hospital care setting--results of the ENDORSE study in Poland. Pol Arch Med Wewn. 2008;118(10):555-61. [PubMed: 19112816].
  • 9. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: The Padua prediction score. J Thromb Haemost. 2010;8(11):2450-7. doi: 10.1111/j.1538-7836.2010.04044.x. [PubMed: 20738765].
  • 10. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e24S-43S. doi: 10.1378/chest.11-2291. [PubMed: 22315264]. [PubMed Central: PMC3278070].
  • 11. Wang TF, Milligan PE, Wong CA, Deal EN, Thoelke MS, Gage BF. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost. 2014;111(1):88-93. doi: 10.1160/TH13-01-0042. [PubMed: 24136071]. [PubMed Central: PMC4505726].
  • 12. Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost. 2011;105(3):444-53. doi: 10.1160/TH10-09-0601. [PubMed: 21136019].
  • 13. Abdar Esfahani M, Sayehmiri F. One decade "narcotic addicted patients with deep vein thrombosis" in st. Alzahra Hospital of Isfahan, Iran. Addict Health. 2014;6(3-4):127-37. [PubMed: 25984280]. [PubMed Central: PMC4354218].
  • 14. Rafizadeh R, Turgeon RD, Batterink J, Su V, Lau A. Characterization of Venous thromboembolism risk in medical inpatients using different clinical risk assessment models. Can J Hosp Pharm. 2016;69(6):454-9. [PubMed: 28123191]. [PubMed Central: PMC5242277].
  • 15. Moorehead KJ, Jeffres MN, Mueller SW. A retrospective cohort analysis of pharmacologic VTE prophylaxis and Padua prediction score in hospitalized patients with chronic liver disease. J Pharm Pract. 2017;30(1):58-63. doi: 10.1177/0897190015611570. [PubMed: 26475125].
  • 16. Nendaz M, Spirk D, Kucher N, Aujesky D, Hayoz D, Beer JH, et al. Multicentre validation of the Geneva risk score for hospitalised medical patients at risk of venous thromboembolism. Thromb Haemostasis. 2014;112(3):531-8. doi: 10.1160/TH13-05-0427.
  • 17. Amin A, Spyropoulos AC, Dobesh P, Shorr A, Hussein M, Mozaffari E, et al. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis. 2010;29(3):326-39. doi: 10.1007/s11239-009-0361-z. [PubMed: 19548071]. [PubMed Central: PMC2837191].
  • 18. Pinjala R; ENDORSE-India Investigators. Venous thromboembolism risk & prophylaxis in the acute hospital care setting (ENDORSE), a multinational cross-sectional study: Results from the Indian subset data. Indian J Med Res. 2012;136(1):60-7. [PubMed: 22885265]. [PubMed Central: PMC3461719].
  • 19. Lukaszuk RF, Dolna-Michno J, Plens K, Czyzewicz G, Undas A. The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: Is pharmacological thromboprophylaxis overused? Contemp Oncol (Pozn). 2018;22(1):31-6. doi: 10.5114/wo.2018.74391. [PubMed: 29692661]. [PubMed Central: PMC5909728].
  • 20. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e278S-325S. doi: 10.1378/chest.11-2404. [PubMed: 22315265]. [PubMed Central: PMC3278063].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments